Altimmune to Participate in Two Upcoming Investor Conferences
Altimmune (NASDAQ:ALT), a late clinical-stage biopharmaceutical company focused on liver and cardiometabolic diseases, has announced its participation in two upcoming investor conferences. Management will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 10:30 a.m. ET, and the H.C. Wainwright Liver Disease Virtual Conference on October 21, 2025, at 7:00 a.m. ET.
Both presentations will feature fireside chats and will be available via webcast through the Events section of Altimmune's website. The company's management team will also be available for one-on-one meetings with investors during these events.
Altimmune (NASDAQ:ALT), un’azienda biofarmaceutica in fase clinica avanzata specializzata in malattie epatiche e cardiometaboliche, ha annunciato la partecipazione a due prossimi appuntamenti con gli investitori. Il management parteciperà al Stifel 2025 Virtual Cardiometabolic Forum il 30 settembre 2025 alle 10:30 ET e al H.C. Wainwright Liver Disease Virtual Conference il 21 ottobre 2025 alle 7:00 ET. Entrambe le presentazioni prevedono sessioni di fireside chat e saranno disponibili in webcast attraverso la sezione Eventi del sito di Altimmune. Il management sarà inoltre disponibile per incontri one-on-one con gli investitori durante questi eventi.
Altimmune (NASDAQ: ALT), empresa biofarmacéutica en fase clínica avanzada centrada en enfermedades hepáticas y cardiometabólicas, ha anunciado su participación en dos próximas conferencias para inversores. La dirección presentará en el Stifel 2025 Virtual Cardiometabolic Forum el 30 de septiembre de 2025 a las 10:30 a.m. ET, y en la H.C. Wainwright Liver Disease Virtual Conference el 21 de octubre de 2025 a las 7:00 a.m. ET. Ambas presentaciones incluirán conversaciones informales (fireside chats) y estarán disponibles por webcast a través de la sección Eventos del sitio web de Altimmune. El equipo directivo también estará disponible para reuniones individuales con inversores durante estos eventos.
Altimmune (NASDAQ:ALT)는 간 및 심혈관 대사 질환에 집중하는 말기 임상 단계의 생물의약 회사로, 두 차례의 다가오는 투자자 컨퍼런스에 참여한다고 발표했습니다. 경영진은 Stifel 2025 Virtual Cardiometabolic Forum를 2025년 9월 30일 오전 10:30 ET에, H.C. Wainwright Liver Disease Virtual Conference를 2025년 10월 21일 오전 7:00 ET에 발표할 예정입니다. 두 발표 모두 파이어사이드 채팅 형식으로 진행되며 Altimmune 웹사이트의 이벤트 섹션을 통해 웹캐스트로 시청할 수 있습니다. 또한 이 기간 동안 투자자와의 일대일 미팅도 가능하다고 회사 경영진이 밝혔습니다.
Altimmune (NASDAQ:ALT), une société biopharmaceutique en phase clinique avancée spécialisée dans les maladies hépatiques et cardiométaboliques, a annoncé sa participation à deux prochaines conférences pour investisseurs. La direction présentera au Stifel 2025 Virtual Cardiometabolic Forum le 30 septembre 2025 à 10h30 ET, et à la H.C. Wainwright Liver Disease Virtual Conference le 21 octobre 2025 à 7h00 ET. Les deux présentations comporteront des sessions de type “fireside chats” et seront disponibles en webcast dans la section Événements du site Web d’Altimmune. L'équipe de direction sera également disponible pour des réunions en tête-à-tête avec les investisseurs durant ces événements.
Altimmune (NASDAQ: ALT), ein fortgeschrittenes klinisches Biopharma-Unternehmen, das sich auf Leber- und kardiometabolische Krankheiten konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt. Das Management wird am Stifel 2025 Virtual Cardiometabolic Forum am 30. September 2025 um 10:30 Uhr ET und an der H.C. Wainwright Liver Disease Virtual Conference am 21. Oktober 2025 um 7:00 Uhr ET teilnehmen. Beide Präsentationen enthalten Fireside-Chats und sind im Webcast über den Bereich Veranstaltungen auf der Altimmune-Website verfügbar. Das Management-Team wird außerdem während dieser Veranstaltungen für Einzelgespräche mit Investoren zur Verfügung stehen.
أولتيموين (ناسداك: ALT)، شركة أدوية حيوية في مرحلة متقدمة تركز على أمراض الكبد والأيض القلبي-الشرياني، أعلنت عن مشاركتها في مؤتمرَين للمستثمرين قادمين. ستقدم الإدارة في Stifel 2025 Virtual Cardiometabolic Forum في 30 سبتمبر 2025 الساعة 10:30 صباحًا بتوقيت شرق الولايات المتحدة، وفي H.C. Wainwright Liver Disease Virtual Conference في 21 أكتوبر 2025 الساعة 7:00 صباحًا بتوقيت شرق الولايات المتحدة. ستتضمن كلا العرضين جلسات fireside chat وستكون متاحة عبر البث عبر قسم الفعاليات على موقع Altimmune الإلكتروني. سيكون فريق الإدارة أيضًا متاحًا لإجراء اجتماعات فردية مع المستثمرين خلال هذه الفعاليات.
Altimmune（纳斯达克股票代码：ALT）是一家处于晚期临床阶段、专注于肝病和心代谢疾病的生物制药公司，宣布将参加两场即将举行的投资者会议。管理层将于2025年9月30日东部时间10:30 AM在Stifel 2025 Virtual Cardiometabolic Forum上发言，及在2025年10月21日东部时间7:00 AM参加H.C. Wainwright Liver Disease Virtual Conference。两场演示均将包含炉边对谈（fireside chats），并可通过 Altimmune 网站“活动”板块的 webcast 收看。公司管理团队也将于这些活动期间与投资者进行一对一会面。
- None.
- None.
GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences:
- Stifel 2025 Virtual Cardiometabolic Forum
Tuesday, September 30, 2025
Fireside Chat at 10:30 a.m. Eastern Time
- H.C. Wainwright Liver Disease Virtual Conference
Tuesday, October 21, 2025
Fireside Chat at 7:00 a.m. Eastern Time
The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.
About Altimmune
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Alcohol Use Disorder (AUD), Alcohol-associated Liver Disease (ALD) and obesity. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on X
Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
This press release was published by a CLEAR® Verified individual.
FAQ
When is Altimmune (ALT) presenting at the Stifel 2025 Virtual Cardiometabolic Forum?
What time is Altimmune's presentation at the H.C. Wainwright Liver Disease Conference?
How can investors access Altimmune's conference presentations?
What type of company is Altimmune (ALT)?
Will Altimmune management be available for individual meetings at these conferences?
